Events Partner Content 1st Molecular Glue Drug Development Summit Advance Molecular Glue Degraders into the Clinic
Events Partner Content 5th Annual Targeted Protein Degradation Summit Deliver Next Generation Degraders to Patients Faster
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
